It was a deal a day in Minnesota last year.
About 375 public and private Minnesota companies acquired or sold a business, in what was the busiest year for corporate transactions since the Great Recession of 2008-09.
The 2015 total transaction value for Minnesota was $65.7 billion, down slightly from $72.2 billion the year before. 2014 was bolstered by Medtronic's $49.9 billion stock-and-cash acquisition of surgical-supply maker Covidien PLC. The largest Minnesota deal in 2015 was a quarter that size.
Nationally, after a six-year run of increased merger-and-acquisition activity, the value of U.S.-based transactions broke through $2 trillion in 2015 for the first time, totaling $2.47 trillion, according to Dealogic.
Mergers and acquisitions were the hottest part of the corporate-finance business. Buyers, whether strategic competitors or financial, such as private equity funds, are using low-cost borrowed money to "buy growth." They are adding to their product lines or expanding geographically through acquisitions more cheaply than they could by investing in organic expansion.
The national deal list was led by Pfizer's proposed $160 billion merger with Allergan and Dell's pending $66 billion acquisition of EMC.
There were up to 226 Minnesota companies sold last year, based on data compiled by Dealogic, Thomson One and S&P Capital IQ. Those transactions were worth more than $30 billion. Not all transactions are reported publicly and the data services often arrive at varying totals.
Minnesota's largest company, Minnetonka-based UnitedHealth Group, paid $12.8 billion to acquire Illinois-based Catamaran Corp., a prescription drug-benefit manager in a deal designed to give UnitedHealth more clout to push back on drug prices. It already was the third-largest player in the nearly $300 billion business of managing prescription-drug benefits for Americans.